The Center for Cell Reprogramming: Current Series
All Seminars are located in Building D
Room - Warwick-Evans
(Unless otherwise noted)
november 5, 2018
kris c. wood, PhD
Department of pharmacology & cancer biology
Dr. Wood's lab is broadly interested in devising methods to better connect cancer patients with effective therapeutic strategies. Meeting this goal is challenging, as patient tumors are heterogeneous, genetically complex, and evolvable. Further, there are many potential drugs that can be assembled in many combinations. To address this challenge, they are developing functional genomic technologies that allow us to systematically map the genetic determinants of drug sensitivity and then connect these to effective therapeutic strategies. Additionally, they are developing analytical approaches rooted in pharmacology, bioinformatics, and statistical/mathematical modeling to study tumor evolution and design selective combination therapies. Beyond purely translational applications, their studies should advance our basic understanding of the architectures of biological signaling networks, and the experimental and computational genomic tools they develop may be useful for systematically studying a range of additional biological processes.
December 5, 2018
anna t. reigel, Phd
profesor, department of oncology and pharmacology
director of research education
lombardi Comprehensive cancer center
Anna Tate Riegel, PhD, is the director for cancer research education at Georgetown Lombardi. Dr. Riegel is Professor of Oncology and Pharmacology at Georgetown University Medical Center. She received her PhD from the University of Wisconsin, at a founding cancer research training program in the United States. She serves at the Principal Investigator for Lombardi’s Tumor Biology Training Grant and has a strong track record in education that includes personally mentoring nine post-doctoral fellows and 13 doctoral candidates. Dr. Riegel has an active laboratory which conducts research on hormone and growth factor receptor interactions in breast, prostate, and pancreatic cancers. Her work aims to develop novel targets for new drugs to treat and prevent cancer. Dr. Riegel’s research is funded by the National Institutes of Health, Department of Defense, and various private foundations.
PAST SPEAKERS FROM OUR CURRENT SERIES
SEPTEMBER 27, 2018
KENNETH S. ZARET, PHD
JOSEPH LEIDY PROFESSOR, DEPARTMENT OF CELL AND DEVELOPMENTAL BIOLOGY
PERELMAN SCHOOL OF MEDICINE
UNIVERSITY OF PENNSYLVANIA
Kenneth S. Zaret, Ph.D. is the Joseph Leidy Professor in the Department of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania. He is also the Director of UPenn’s Institute for Regenerative Medicine (2014-). Dr. Zaret did his graduate work on yeast genetics with Dr. Fred Sherman in the Department of Radiation Biology and Biophysics at the University of Rochester (1977-1982) and his postdoctoral work on steroid hormone regulation with Dr. Keith Yamamoto in the Department of Biochemistry and Biophysics (1982-1985) at the University of California, San Francisco. From 1986 to 1999 he was in the Biochemistry Section, and then in the Department of Molecular Biology, Cell Biology, and Biochemistry at Brown University Medical School, where he attained the rank of Professor. From 1999 to 2009, Dr. Zaret was a Senior Member and Leader of the Cell and Developmental Biology Program at the Fox Chase Cancer Center, where he held the W.W. Smith Chair in Cancer Research. He also initiated the Epigenetics and Progenitor Cells Program at Fox Chase. Dr. Zaret moved to UPenn in 2009, where he served as Associate Director of the Institute for Regenerative Medicine and Co-Director of the Epigenetics Program until 2014. Dr. Zaret is a member of the Cell and Molecular Biology Graduate Program at UPenn.
October 23, 2018
Daohong Zhou, M.D.
Professor of Pharmacodynamics and Radiation Oncology
Harry E. Innes Professorship of Cancer Research
Associate Director for Translation and Drug Development
University of florida
Daohong Zhou, MD is a Professor in the Department of Pharmacodynamics at the College of Pharmacy and a Professor in the Department of Radiation Oncology at the College of Medicine, University of Florida (UF) at Gainesville. He serves as the Associate Director for Translation and Drug Development and the Harry E. Innes Professorsip of Cancer Research at the UF Health Cancer Center. Dr. Zhou received his medical (1978-1983) and graduate (1983-1986) training from Yunyany Medical College of Tongji Medical University and Henan Medical University, respectively; and his postdoctoral training (1990-1992) at the Johns Hopkins University School of Medicine. Before he joined UF in 2018, he was a Professor of Pharmaceutical Sciences and the Deputy Director of the Division of Radiation Health at the College of Pharmacy and the Associate Director for Basic Research at the Winthrop P. Rockefeller Cancer Institute in the University of Arkansas for Medical Sciences (UAMS).
If you are interested in being a speaker at one of our Center for Cell Reprogramming Seminars, or if you have a topic you would like to hear please contact us here.